FDA Approves Nivolumab for Completely Resected Stage IIB/C Melanoma
Metastatic subcutaneous melanoma Image courtesy of DermNetZ A paradigm shift is occurring in the treatment of patients with melanoma. In October 2023, the FDA approved nivolumab (Opdivo; Bristol Myers Squibb) for patients 12 years of age and older with completely resected stage IIB/C melanoma.one This latest approval is considered a breakthrough for patients with advanced… Read More »